MPMichael D. Peake

Michael D. Peake

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael D. Peake has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Aileen B. Chen

    Dept of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA

    1 shared publication
  • Anna Gavin

    Queen’s University Belfast

    1 shared publication
  • Annelotte C.M. van Bommel

    International Consortium for Health Outcomes Measurement, Cambridge, MA, USA Dutch Institute for Clinical Auditing, Leiden, The Netherlands Both authors contributed equally

    1 shared publication
  • Anoop J Chauhan

    Consultant Respiratory Physician and Director of Research & Development, Portsmouth Hospitals NHS Trust, Portsmouth, England

    1 shared publication
  • Benjamin D. Kozower

    Dept of Thoracic Surgery, University of Virginia Health System, Charlottesville, VA, USA

    1 shared publication
  • C M Richardson

    Department of Respiratory Medicine, Nottingham City Hospital, Nottingham NG5 1PB, UK

    1 shared publication

Latest Publications

  • Open Access

    Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

    by Michael Eden, Samantha Harrison, Michelle Griffin, Mats Lambe, David Pettersson, Anna Gavin, David H. Brewster, Yulan Lin, Tom B. Johannesen, Roger L. Milne, et al.


  • Open Access

    Defining a standard set of patient-centred outcomes for lung cancer

    by Kimberley S. Mak, Annelotte C.M. van Bommel, Caleb Stowell, Janet L. Abrahm, Matthew Baker, Clarissa S. Baldotto, David R. Baldwin, Diana Borthwick, David P. Carbone, Aileen B. Chen, et al.

    In lung cancer, outcome measurement has been mostly limited to survival. Proper assessment of the value of lung cancer treatments, and the performance of institutions delivering care, requires more comprehensive measurement of standardised outcomes.The International Consortium for Health Outcomes Measurement convened an international, multidisciplinary working group of patient representatives, medical oncologists, surgeons, radiation oncologists, pulmonologists, palliative care specialists, registry experts and specialist nurses to review existing data and practices. Using a modified Delphi method, the group developed a consensus recommendation (“the set”) on the outcomes most essential to track for patients with lung cancer, along with baseline demographic, clinical and tumour characteristics (case-mix variables) for risk adjustment.The set applies to patients diagnosed with nonsmall cell lung cancer and small cell lung cancer. Our working group recommends the collection of the following outcomes: survival, complications during or within 6 months of treatment and patient-reported domains of health-related quality of life including pain, fatigue, cough and dyspnoea. Case-mix variables were defined to improve interpretation of comparisons.We defined an international consensus recommendation of the most important outcomes for lung cancer patients, along with relevant case-mix variables, and are working to support adoption and reporting of these measures globally.


  • Open Access

    A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial

    by Samal Gunatilake, Fraser Jh Brims, Carole Fogg, Iain Lawrie, Nick Maskell, Karen Forbes, Najib Rahman, Steve Morris, Reuben Ogollah, Stephen Gerry, et al.

    Malignant pleural mesothelioma is an incurable cancer caused by exposure to asbestos. The United Kingdom has the highest death rate from mesothelioma in the world and this figure is increasing. Median survival is 8 to 12 months, and most patients have symptoms at diagnosis. The fittest patients may be offered chemotherapy with palliative intent. For patients not fit for systemic anticancer treatment, best supportive care remains the mainstay of management. A study from the United States examining advanced lung cancer showed that early specialist palliative care input improved patient health related quality of life and depression symptoms 12 weeks after diagnosis. While mesothelioma and advanced lung cancer share many symptoms and have a poor prognosis, oncology and palliative care services in the United Kingdom, and many other countries, vary considerably compared to the United States. The aim of this trial is to assess whether regular early symptom control treatment provided by palliative care specialists can improve health related quality of life in patients newly diagnosed with mesothelioma. This multicentre study is an non-blinded, randomised controlled, parallel group trial. A total of 174 patients with a new diagnosis of malignant pleural mesothelioma will be minimised with a random element in a 1:1 ratio to receive either 4weekly regular early specialist symptom control care, or standard care. The primary outcome is health related quality of life for patients at 12 weeks. Secondary outcomes include health related quality of life for patients at 24 weeks, carer health related quality of life at 12 and 24 weeks, patient and carer mood at 12 and 24 weeks, overall survival and analysis of healthcare utilisation and cost. Current practice in the United Kingdom is to involve specialist palliative care towards the final weeks or months of a life-limiting illness. This study aims to investigate whether early, regular specialist care input can result in significant health related quality of life gains for patients with mesothelioma and if this change in treatment model is cost-effective. The results will be widely applicable to many institutions and patients both in the United Kingdom and internationally. Current controlled trials ISRCTN18955704 . Date ISRCTN assigned: 31 January 2014.


  • Open Access

    Symptoms and the early diagnosis of lung cancer

    by S S Birring, M D Peake

    Lung cancer is the leading cause of cancer death in the western world, resulting in nearly 30 000 deaths in England and Wales in 2002.1 Advances in the management of breast, cervical, and prostate cancer have led to improved survival rates, whereas mortality from lung cancer has remained largely unchanged.2 Even the best reported 5 year survival rates for lung cancer are only 10–15%3, 4 and, in England, in patients diagnosed between 1993 and 1995 the survival rate was only 5.5% at 5 years and 22% at 1 year.5


  • Open Access

    Endoscopic (oesophageal) ultrasound guided fine needle aspiration (EUS-FNA)

    by C M Richardson, M D Peake

    The management of lung cancer depends to a great extent on its histological type and the stage of disease. Although most patients with non-small cell lung cancer (NSCLC) have advanced disease at presentation, approximately 30% have tumour confined to the lung and locoregional lymph nodes. For these patients surgery offers the best hope of a cure. Despite apparent complete resection, 5 year survival rates after surgery are approximately 40–50%.1 This highlights the importance of accurately staging lung cancer to determine resectability and provide prognostic information.

  • Open Access

    Ageism in the management of lung cancer

    by Michael D Peake, Sandy Thompson, Derek Lowe, Michael G Pearson, Participating Centres

    Background: age‐related differences in the treatment of lung cancer patients have been reported in the past, but most previous studies have not recorded case‐mix factors, nor have they studied the impact of such ageism on survival. Methods: a questionnaire‐based study of diagnostic and case‐mix factors was carried out across 48 hospital Trusts in the UK between 1997 and 1998. We identified 1,652 patients and followed through with regard to their treatment and survival for 6 months after diagnosis. Results: the median age of the population was 69 years, and for this analysis, was divided into three age groups: under 65 years, 65–74 and 75 years and over. There were significant inverse correlations between age and histological diagnosis, any active treatment and survival, even when corrected for case‐mix factors and non‐cancer causes of death. For example, the surgical resection rate in patients with confirmed non‐small cell lung cancer with good performance status, no chronic obstructive pulmonary disease and limited disease was 37% in the younger patients compared with 15% in those 75 and over. The overall mortality rates at 6 months ranged from 42% in patients under 65 to 58% in the over 75s. Conclusions: this national study of lung cancer care in the UK has shown large age‐related differences in management and survival in patients with lung cancer, largely independent of case‐mix factors. The reasons for this are complex but such under‐treatment in the elderly may be one factor underlying the poor outcomes in lung cancer patients in the UK.